Figure 2
Pharmacodynamic effects. Phospho-Akt308 concentrations in circulating B cells (from normal subjects, N = 6) or CLL cells (from patients receiving idelalisib at 100 mg/dose bid (N = 7) or ≥150 mg/dose bid (N = 20)).
Pharmacodynamic effects. Phospho-Akt308 concentrations in circulating B cells (from normal subjects, N = 6) or CLL cells (from patients receiving idelalisib at 100 mg/dose bid (N = 7) or ≥150 mg/dose bid (N = 20)).
